

2.2
2.1
Cont

wherein said pharmaceutical composition further comprises another antiviral agent.

26. (Amended) A method [composition] according to claim 25, wherein said antiviral agent is an acyclic nucleoside, an interferon, a renal excretion inhibitor, a nucleoside transport inhibitor, a 2',3'-dideoxynucleoside, an immunomodulator, erythropoietin, ampligen, thyomodulin, thymopentin, foscarnet, ribavirin, or an inhibitor of HIV binding to CD4.

Please add the following new firms.

J
2.3 **27.** A method according to claim 26, wherein the amount of said compound is or pharmaceutically acceptable salt
10-1500 mg.

seed
2.1 **28.** A method according to claim 23, wherein the amount of said compound is
20-1000 mg.

29. A method according to claim 23, wherein the amount of said compound is
50-700 mg.

30. A method according to claim 23, wherein said composition contains an amount of the (+)-enantiomer corresponding to said compound of no more than 5% w/w, relative to the combined weight of (-) and (+) enantiomers.

seed
2.2 **31.** A method according to claim 30, wherein said composition contains an amount of the (+)-enantiomer of no more than 2% w/w.

J **32.** A method according to claim 31, wherein said composition contains an amount of the (+)-enantiomer of no more than 1% w/w.

J **33.** A method according to claim 26, wherein said compound and said other or pharmaceutically acceptable salt antiviral agent are administered sequentially.

J **34.** A method according to claim 26, wherein said compound and said other or pharmaceutically acceptable salt antiviral agent are administered simultaneously.

seed
2.4 **35.** A method according to claim 23, wherein said mammal is a human.
36. A method according to claim 25, wherein said mammal is a human.
37. A method for treating a mammal suffering from HIV infection comprising: administering to said mammal a pharmaceutical composition comprising the compound (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one and a pharmaceutically acceptable carrier, wherein said compound is administered at a dosage of 0.1-750 mg/kg of body weight per day.